Affymax's Peginesatide May Be Tough Sell To ODAC As ESAs Cast Long Showdow

Safety concerns over erythropoiesis-stimulating agents seem to extend to Affymax's peginesatide, and since it lacks an efficacy edges over these drugs in treating anemia due to chronic kidney disease, an approval basis is unclear.